Status:

COMPLETED

Boom-IBD Clinical Trial

Lead Sponsor:

Boomerang Medical

Conditions:

IBD

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Feasibility study of neuromodulation in patients with IBD.

Detailed Description

The study will evaluate responses of patients with IBD treated with neuromodulation at various intervals.

Eligibility Criteria

Inclusion

  • General Inclusion Criteria:
  • Male or female
  • 18 to 75 years of age
  • Diagnosed with Crohn's Disease or ulcerative colitis
  • Ability and willingness to consent to participate by signing the informed consent form
  • Ability to comply with the protocol and willingness to comply with all follow-up requirements
  • Still have part or all of their colon
  • General Exclusion Criteria (The subject must not meet ANY of the following criteria):
  • Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound the results of the study
  • Any psychiatric or personality disorder at the discretion of the study investigator
  • Any active bacterial infection with a risk of bacteremia or sepsis (e.g. presence of abscess)
  • Active clostridium difficile infection of the colon
  • Active cytomegalovirus (CMV) infection of the colon
  • Evidence of colonic perforation
  • Fulminant colitis requiring emergency surgery
  • Microscopic, ischemic or infectious colitis
  • Unresected neoplasia of the colon
  • Colonic stricture unable to pass a colonoscope
  • History of cancer including melanoma (except for localized skin cancers) within 2 years
  • Participation in another clinical trial within the past 30 days of device implant
  • Investigational drug for the treatment of inflammatory bowel disease within 6 months of device implant
  • Inability to operate the patient programmer

Exclusion

    Key Trial Info

    Start Date :

    October 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 6 2024

    Estimated Enrollment :

    40 Patients enrolled

    Trial Details

    Trial ID

    NCT05414955

    Start Date

    October 1 2022

    End Date

    December 6 2024

    Last Update

    June 29 2025

    Active Locations (8)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (8 locations)

    1

    Phillip Fleshner, Inc.

    Los Angeles, California, United States, 90048

    2

    Palo Alto Medical Foundation Research Institute

    Palo Alto, California, United States, 94301

    3

    CU Anschutz

    Aurora, Colorado, United States, 80045

    4

    Kansas Gastroenterology

    Wichita, Kansas, United States, 67226-8119